openpr.com

www.openpr.com Β·

Negative

intratumoral cancer therapies market expected to witness

TAX_DISEASE_NEUROENDOCRINE_TUMORSWB_1614_NUTRITIONAL_PROGRAMSWB_1609_FOOD_AND_IN_KIND_TRANSFERSWB_1615_THERAPEUTIC

The full article is on the original publisher site. This page only shows the headline and a very short excerpt.

About the publisher

openpr.com is one of the en-language news outlets that News Analysis aggregates. Coverage from this source appears in our global feed alongside the publisher's own reporting.

Topic context

openpr.com files this story under "tax disease neuroendocrine tumors" in the GDELT knowledge graph. News Analysis surfaces coverage based on the same open classification taxonomy.

intratumoral cancer therapies market expected to witness | openpr.com β€” News Analysis